🚨 Three months ago, @BaysideGrowth published the definitive legal breakdown on why $HIMS could continue selling compounded GLP-1s, even after the shortage ended. Today, $NVO abruptly terminated its deal with $HIMS, apparently upset that $HIMS is still selling compounded GLP-1s. For anyone looking to examine the actual letter of the law, the Food, Drug, & Cosmetics Act, 503A compounding exemptions, intellectual property issues, what might happen if $NVO sues, and much more, there is no more important report than this one. (link below)

87.84K

The content on this page is provided by third parties. Unless otherwise stated, OKX is not the author of the cited article(s) and does not claim any copyright in the materials. The content is provided for informational purposes only and does not represent the views of OKX. It is not intended to be an endorsement of any kind and should not be considered investment advice or a solicitation to buy or sell digital assets. To the extent generative AI is utilized to provide summaries or other information, such AI generated content may be inaccurate or inconsistent. Please read the linked article for more details and information. OKX is not responsible for content hosted on third party sites. Digital asset holdings, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition.